title: Ablation of human colon carcinoma in nude mice by 131I-labeled monoclonal anti-carcinoembryonic antigen antibody F(ab')2 fragments.
abstract: Pooled F(ab')2 fragments of three MAbs against distinct epitopes of carcinoembryonic antigen (CEA) were used for radioimmunotherapy of nude mice bearing a subcutaneous human colon carcinoma xenograft. 9-10 d after transplantation when tumor nodules were in exponential growth, 36 mice were treated by intravenous injection of different amounts of 131I-labeled MAb F(ab')2. All 14 mice injected with a single dose of 2,200 (n = 10) or 2,800 microCi (n = 4) showed complete tumor remission. 8 of the 10 mice treated with 2,200 microCi survived in good health for 1 yr when they were killed and shown to be tumor free. Four of nine other mice treated with four fractionated doses of 400 microCi showed no tumor relapse for more than 9 mo. In contrast, all 15 mice injected with 1,600-3,000 microCi 131I-control IgG F(ab')2 showed tumor growth retardation of only 1-4 wk, and 15 of 16 mice injected with unlabeled anti-CEA MAb F(ab')2 showed unmodified tumor progression as compared with untreated mice. From tissue radioactivity distributions it was calculated that by an injection of 2,200 microCi 131I-MAb F(ab')2 a mean dose of 8,335 rad was selectively delivered to the tumor, while the tissue-absorbed radiation doses for the normal organs were: peripheral blood, 2,093; stomach, 1,668; kidney, 1,289; lung, 1,185; liver, 617; spleen, 501; small intestine, 427; large intestine, 367; bone, 337; and muscle, 198. These treatments were well tolerated since out of 19 mice with complete tumor remission only 4 required bone marrow transplantation and 17 were in good health for 6-12 mo of observation. The results demonstrate the selective destruction of established human colon carcinoma transplants by intravenous injection of either single or fractionated doses of 131I-MAb F(ab')2.
authors.affiliation: Ludwig Institute for Cancer Research, Lausanne Branch, Switzerland.
authors.forename: F
authors.initials: F
authors.lastname: Buchegger
authors.forename: C
authors.initials: C
authors.lastname: Pfister
authors.forename: K
authors.initials: K
authors.lastname: Fournier
authors.forename: F
authors.initials: F
authors.lastname: Prevel
authors.forename: M
authors.initials: M
authors.lastname: Schreyer
authors.forename: S
authors.initials: S
authors.lastname: Carrel
authors.forename: J P
authors.initials: JP
authors.lastname: Mach
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D002272:Carcinoembryonic Antigen / Q000276:immunology*; D002277:Carcinoma / Q000473:pathology / Q000628:therapy*; D003110:Colonic Neoplasms / Q000473:pathology / Q000628:therapy*; D004306:Dose-Response Relationship, Immunologic; D004334:Drug Administration Schedule; D005355:Fibrosis; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage*; D007457:Iodine Radioisotopes / Q000008:administration & dosage; D008297:Male; D051379:Mice; D008819:Mice, Nude; D011786:Quality Control; D012074:Remission Induction
chemical_list: D000911:Antibodies, Monoclonal; D002272:Carcinoembryonic Antigen; D007140:Immunoglobulin Fab Fragments; D007457:Iodine Radioisotopes